% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Rosen:902026,
author = {Rosen, Jurij and Stoffels, Gabriele and Lohmann, Philipp
and Bauer, Elena K. and Werner, Jan-Michael and Wollring,
Michael and Rapp, Marion and Felsberg, Jörg and Kocher,
Martin and Fink, Gereon R. and Langen, Karl-Josef and
Galldiks, Norbert},
title = {{P}rognostic value of pre-irradiation {FET} {PET} in
patients with not completely resectable {IDH}-wildtype
glioma and minimal or absent contrast enhancement},
journal = {Scientific reports},
volume = {11},
number = {1},
issn = {2045-2322},
address = {[London]},
publisher = {Macmillan Publishers Limited, part of Springer Nature},
reportid = {FZJ-2021-03984},
pages = {20828},
year = {2021},
abstract = {In glioma patients, complete resection of the
contrast-enhancing portion is associated with improved
survival, which, however, cannot be achieved in a
considerable number of patients. Here, we evaluated the
prognostic value of O-(2-[18F]-fluoroethyl)-L-tyrosine (FET)
PET in not completely resectable glioma patients with
minimal or absent contrast enhancement before temozolomide
chemoradiation. Dynamic FET PET scans were performed in 18
newly diagnosed patients with partially resected (n = 8)
or biopsied (n = 10) IDH-wildtype astrocytic glioma
before initiation of temozolomide chemoradiation. Static and
dynamic FET PET parameters, as well as contrast-enhancing
volumes on MRI, were calculated. Using receiver operating
characteristic analyses, threshold values for which the
product of paired values for sensitivity and specificity
reached a maximum were obtained. Subsequently, the
prognostic values of FET PET parameters and
contrast-enhancing volumes on MRI were evaluated using
univariate Kaplan–Meier and multivariate Cox regression
(including the MTV, age, MGMT promoter methylation, and
contrast-enhancing volume) survival analyses for
progression-free and overall survival (PFS, OS). On MRI,
eight patients had no contrast enhancement; the remaining
patients had minimal contrast-enhancing volumes (range,
0.2–5.3 mL). Univariate analyses revealed that smaller
pre-irradiation FET PET tumor volumes were significantly
correlated with a more favorable PFS (7.9 vs. 4.2 months;
threshold, 14.8 mL; P = 0.012) and OS (16.6 vs. 9.0
months; threshold, 23.8 mL; P = 0.002). In contrast,
mean tumor-to-brain ratios and time-to-peak values were only
associated with a longer PFS (P = 0.048 and
P = 0.045, respectively). Furthermore, the
pre-irradiation FET PET tumor volume remained significant in
multivariate analyses (P = 0.043), indicating an
independent predictor for OS. Our results suggest that
pre-irradiation FET PET parameters have a prognostic impact
in this subgroup of patients.},
cin = {INM-3 / INM-4},
ddc = {600},
cid = {I:(DE-Juel1)INM-3-20090406 / I:(DE-Juel1)INM-4-20090406},
pnm = {5252 - Brain Dysfunction and Plasticity (POF4-525)},
pid = {G:(DE-HGF)POF4-5252},
typ = {PUB:(DE-HGF)16},
pubmed = {34675225},
UT = {WOS:000709931300019},
doi = {10.1038/s41598-021-00193-x},
url = {https://juser.fz-juelich.de/record/902026},
}